alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 26–50 of 84 studies with an author at Leiden University Medical Center (NL) (page 2 of 4) · 27,780 in the whole library · How the 0–100 score works

Download bibliography of these 84 studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Other institutions

From OpenAlex; 13,259 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Circulating metabolites and general cognitive ability and dementia: Evidence from 11 cohort studies

✓ Peer-reviewed alzhub usefulness score 60 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2018-01-06

Circulating metabolites were consistently associated with cognition, dementia, and lifestyle factors, opening new avenues for prevention of cognitive decline and dementia. 4 key findings →

Participants: 25,872 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Improving comfort in people with dementia and pneumonia: a cluster randomized trial

✓ Peer-reviewed alzhub usefulness score 59 out of 100. BMC medicine 2016-08-11

When compared to usual care, the practice guideline for optimal symptom relief did not relieve discomfort and symptoms in nursing home residents with dementia and pneumonia. 4 key findings →

Design: randomized controlled trial Participants: 16 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Burden and care time for dementia caregivers in the LIVE@Home.Path trial

✓ Peer-reviewed alzhub usefulness score 59 out of 100. Alzheimer s & Dementia 2025-03-01

Two hundred eighty dyads were enrolled. Caregivers during the intervention period reported lower levels of RSS of 0.7 points (standard deviation [SD]: 0.8) compared to the caregivers in the control period. 5 key findings →

Design: randomized controlled trial Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Development and Validation of a Dementia Risk Prediction Model in the General Population: An Analysis of Three Longitudinal Studies

✓ Peer-reviewed alzhub usefulness score 57 out of 100. The American journal of psychiatry 2018-12-11

Identification of individuals at high risk of dementia is essential for development of prevention strategies, but reliable tools are lacking for risk stratification in the population. 4 key findings →

Participants: 181 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Amyloid imaging of dutch-type hereditary cerebral amyloid angiopathy carriers

✓ Peer-reviewed alzhub usefulness score 56 out of 100. Annals of neurology 2019-08-12

D-CAA M + showed greater age-dependent FLR PiB retention (p - , and serially imaged asymptomatic M + demonstrated greater longitudinal increases (p = 0.004). 3 key findings →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Mutation of the Alzheimer's Disease Amyloid Gene in Hereditary Cerebral Hemorrhage, Dutch Type

✓ Peer-reviewed alzhub usefulness score 56 out of 100. Science 1990-06-01

An amyloid protein that precipitates in the cerebral vessel walls of Dutch patients with hereditary cerebral hemorrhage with amyloidosis is similar to the amyloid protein in vessel walls and senile plaques in brains of patients with Alzheimer's disease, Down syndrome, and sporadic cerebral amyloid angiopathy.

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Glial Fibrillary Acidic Protein and Neurofilament Light Reference Intervals in Healthy Individuals

✓ Peer-reviewed alzhub usefulness score 55 out of 100. JAMA Network Open 2026-05-14

In 7989 cognitively unimpaired participants (median [range] age, 54 [30-90] years; 4877 [61.3%] female; mean [SD] BMI, 25.9 [4.2]; mean [SD] eGFR, 80.7 [14.7] mL/min/1.73 m2), older age, lower BMI, and reduced kidney function were associated with increased NfL and GFAP concentrations; female sex was associated with increased GFAP concentrations. 5 key findings →

Design: cross-sectional Participants: 179 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Identifying pathways to the prevention of dementia: the Netherlands consortium of dementia cohorts

✓ Peer-reviewed alzhub usefulness score 54 out of 100. BMC Neurology 2025-02-12

We increased the findability, accessibility, interoperability and reusability (FAIR) status of the cohorts through harmonization of data across cohorts, implementation of medical imaging repositories for scan management, implementation of the Personal Health Train infrastructure and provision of meta-data in existing cohort catalogues. 5 key findings →

Design: meta-analysis Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Identifying triggers for optimal timing of advance care planning in electronic primary health care records: a nested case-control study

✓ Peer-reviewed alzhub usefulness score 53 out of 100. BMJ Open 2025-11-01

We included 17098 records, 4139 from deceased individuals (mean age 81) and 12959 from living individuals (mean age 79). 4 key findings →

Design: case-control study Participants: 17,098 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Minocycline for sporadic and hereditary cerebral amyloid angiopathy (BATMAN): study protocol for a placebo-controlled randomized double-blind trial

✓ Peer-reviewed alzhub usefulness score 53 out of 100. Trials 2023-06-05

The results of this proof-of-principle study will be used to assess the potential of target engagement of minocycline for CAA. 1 key finding →

Participants: 60 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Impact of molecular imaging on the diagnostic process in a memory clinic

✓ Peer-reviewed alzhub usefulness score 52 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2012-11-16

[(11)C]PIB scans were positive in 40 of 66 (61%) patients with a clinical diagnosis of Alzheimer's disease (AD), 5 of 18 (28%) patients with frontotemporal dementia (FTD), 4 of 5 (80%) patients with Lewy body dementia, and 3 of 10 (30%) patients with other dementias. [(18)F]FDG uptake patterns matched the clinical diagnosis in 38 of 66 (58%) of AD patients, and in 6 of 18 (33%) FTD patients. 4 key findings →

Participants: 39 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Abeta is targeted to the vasculature in a mouse model of hereditary cerebral hemorrhage with amyloidosis

✓ Peer-reviewed alzhub usefulness score 52 out of 100. Nature neuroscience 2004-08-15

The E693Q mutation in the amyloid beta precursor protein (APP) leads to cerebral amyloid angiopathy (CAA), with recurrent cerebral hemorrhagic strokes and dementia. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Occurrence of advance care planning for persons with dementia, cancer and other chronic-progressive diseases in general practice: longitudinal analysis of data from health records linked with administrative data

✓ Peer-reviewed alzhub usefulness score 50 out of 100. BMJ Open 2025-09-01

In adjusted analyses, the rate of first ACP conversation for persons with organ failure was the lowest (IRR 0.70 (95% CI 0.68 to 0.73)). 5 key findings →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Resting-state functional MR imaging: a new window to the brain

✓ Peer-reviewed alzhub usefulness score 49 out of 100. Radiology 2014-07-01

Resting-state (RS) functional magnetic resonance (MR) imaging constitutes a novel paradigm that examines spontaneous brain function by using blood oxygen level-dependent contrast in the absence of a task. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed